Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351275 | 0.85 | KDM4E (0.62) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL6961837 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL16399970 | 0.84 | HTT (0.56) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL304546 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL951538 | 0.82 | KMT2A (0.59) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL3093282 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL26077281 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL28550674 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL28546986 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL19717239 | 0.81 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9AGRIN2BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | SMN1; SMN2 2545/4885NPC1 1473/4885RAB9A 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.